Three aspects of Hubei basic drug bidding catalogue policy

Source: medical economics Daily, July 5, 2014, published the 2014 edition of Hubei Province basic drug centralized bidding catalogue In 2014, Hubei Province will invite bids for 800 varieties (including dosage and specification) in the bidding of basic drugs According to the insiders, with the publicity of bidding scheme of Hubei basic drugs, the determination of usage proportion of basic drugs, the determination of management method of basic drug settlement and bidding catalogue, Hubei basic drug bidding preparation work is basically completed, and the formal bidding is only waiting for the final bidding scheme to be finalized The reporter "left room" for differential pricing compared the 153 new non catalogue drugs publicized at the beginning of the year in Hubei with the catalogue published this time Only one variety of 153 varieties has changed, and more than 80% of the new Chinese patent medicines are still exclusive varieties In fact, in May this year, Hubei Province published the work plan for 2014 concentrated procurement of essential drugs in Hubei Province (Draft for comments), which is interpreted by the industry as tending to moderate, fully considering the quality factor, foreign-funded enterprises, local scale enterprises or can enjoy the policy dividend, and small and medium-sized pharmaceutical enterprises are facing a new round of industry reshuffle According to the preliminary plan, the procurement period is 2 years, and the bidding scope is for medical institutions implementing base drugs outside Wuhan The proportion of the economic and technical bid to the commercial bid is 6:4, and the sterile preparation that fails to pass the new GMP will not be accepted for bidding In the scoring, there are two price levels: differentiated pricing and unified pricing The differentiated pricing varieties can get higher scores In the bidding rules, the traditional single bidding principle is broken, and the lowest price and the higher comprehensive score are taken to win the bidding At the same time, Hubei Province also leaves room for the quality level of non ordinary GMP According to the provisions of the preliminary plan, the products in the bidding catalogue and the bid winning catalogue for the centralized procurement of drugs for medical institutions above level II in Hubei Province in 2013 must participate in the centralized bidding, such as high quality and good price, separately priced varieties and other non ordinary GMP For drugs of quality level, if the base drug fails to win the bid but belongs to the last round of non base drug winning varieties, they can still be sold as non base drugs in medical institutions above level II This product specification is only sold in medical institutions above level II and is not "included in the procurement management of basic drugs" From the perspective of Bidding Schemes in Shandong, Anhui, Hunan, Hubei and other provinces, the "only low price" mode of bidding for basic drugs is gradually changing, which not only gives high scores to large-scale enterprises in the quality score, but also tends to be divided into high-quality enterprises in the quality level It is worth noting that the notice on deepening the work of medical reform in 2014 issued in late June in Hubei Province emphasized that county-level public hospitals should give priority to the use of basic drugs and increase the proportion of basic drugs used in the second and third level hospitals The proportion of basic drugs used and sold in the second level medical institutions reached 40% - 50%, of which 50% was implemented in the reform of medical institutions in the public hospitals Above, the proportion of basic drugs used and sold by three-level medical institutions reaches 25% - 30%; further strengthen the centralized purchasing mechanism of basic drugs, take the new GMP certification as an important indicator of quality evaluation; strengthen the management of basic drugs distribution and payment collection, strictly implement the market clearing system, and increase the punishment for enterprises that do not distribute in time On July 3, Hubei basic drug purchase center also issued the "basic drug purchase settlement method", adopting the principle of "who purchases and uses, who pays for the goods" The basic medical institutions are responsible for raising the money, the counties (cities, districts) are responsible for collecting the money, and the Province is the unit for centralized payment The provincial drug purchase center has set up a special account for payment settlement of basic drugs and a provincial revolving fund for Centralized Settlement of basic drugs The special account is for special use, and the special fund is for special use It is responsible for signing purchase and sales contracts with suppliers and settling the payment uniformly This provides the guarantee of payment settlement for the implementation of the basic drug system In addition, the settlement cycle is also specified, in principle, from the completion of drug warehousing acceptance to the payment of no more than 30 days At the same time, a strict integrity record and market clearance system are established If the supply enterprise does not supply goods without justified reasons and the supply is not timely, and in the last settlement cycle, the distribution rate does not reach 90%, the centralized payment will be suspended Since the end of last year, Hubei has repeatedly notified and interviewed the production enterprises with untimely supply and illegal distribution In May of this year, Hubei also issued the document "Regulations on the management of bad records in the field of purchase and sales", which defines the bad records, which are divided into three aspects: commercial bribery, bidding procurement and procurement use Among them, bidding maliciously at a price lower than the cost, increasing the price of the winning products without authorization or in disguised form, failing to entrust the winning varieties to the distribution enterprise for distribution (except for direct distribution by the production enterprise), failing to distribute or not delivering on time, replacing the winning varieties with non winning varieties, etc., will be included in the bad record of bidding and procurement, and the bid winning qualification will be cancelled and the enterprise will be treated accordingly according to the circumstances Penalties such as reduction of business score and non purchase of medical products "If an enterprise maliciously bids at a low price and fails to deliver on time, it will disrupt the market order and increase the punishment, which will enable the enterprise to first measure whether there is profit space for the enterprise when bidding, rather than winning the bid in order to win the bid; if the distribution rate continues to fail to meet the standard, 2 During the year, all basic drug varieties of the enterprise are forbidden to participate in the bidding, which is believed to have a significant impact on the enterprise " Hubei Provincial Health and Family Planning Commission to the reporter said.